



CURRICULUM VITAE

Cengiz GEMICI MD

Tepeören Mah. Kılıç Ali Reis Bulvarı
Akfırat Evleri No:114 Tuzla
Istanbul/TURKEY

(0 532) 578 07 02
cegemici@yahoo.com

EDUCATION AND PROFESSIONAL EMPLOYMENT

- 1984 – 1990 : Marmara University Faculty of Medicine, Istanbul, Turkey.
- 1990 – 1994 : Residency at Radiation Oncology Department of SSK Okmeydani Hospital Istanbul, Turkey.
- 1994 – 1995 : Fellowship, Radiation Oncology Department, Tenon Hospital, Paris, France (Boursier du Collège de Médecine des Hopitaux de Paris).
- 1995 – 1996 : Oncology Residency, Radiation and Medical Oncology Department, Tenon Hospital, Paris, France (Attestation de Formation Spécialisée Approfondie de Cancérologie, Université Paris XI, Faculté de Médecine Paris-Sud).
- 1996 – 1997 : Medical Oncology Residency, Medical Oncology Department, Tenon Hospital, Paris, France (Attestation de Formation Spécialisée Approfondie d'Oncologie Médicale, Université Paris XI, Faculté de Médecine Paris-Sud).

WORK EXPERIENCE

- 1998 – 2000 : Military Service, Gulhane Military Medical Academy
Department of Radiation Oncology, Ankara Turkey.
- 2000 – 2014 : Staff Specialist in Radiation Oncology Department
Kartal Training and Research Hospital, Istanbul Turkey.
- 2014 –2020 : Training and Administrative Coordinator of Radiation Oncology Department
Kartal Training and Research Hospital, Istanbul Turkey.
- 2017- : Appointment as Associate Professor of Radiation Oncology.
- 2024- : Appointment as Professor of Radiation Oncology.
- 2020- : Coordinator of Radiation Oncology at Medical Park Hospital Group - Istanbul

FOREIGN LANGUAGES

Read, write, speak high level of English and French.

SOCIETY MEMBERSHIPS

American Society of Clinical Oncology (ASCO)
American Society of Therapeutic Radiology and Oncology (ASTRO)

AREAS of INTEREST

Lung and Gastrointestinal Cancers. Organ preservation approaches in cancer, Head and Neck, Esophageal and Rectal Cancer.

PERSONAL INFORMATION

Born on 20th Sempember 1966, Ankara. Married.

INTERNATIONAL PUBLICATIONS

1- Covid-19 outbreak in a major radiation oncology department; which lessons should be taken?

Gemici C, Yaprak G.

Radiother Oncol. 2020

2- Stereotactic Radiotherapy in Recurrent Glioblastoma: A Valid Salvage Treatment Option.

Yaprak G, Isik N, Gemici C, Pekyurek M, Ceylaner Bıçakcı B, Demircioglu F, Tatarlı N.

Stereotact Funct Neurosurg. 2020

3- CT Derived Hounsfield Unit: An Easy Way to Determine Osteoporosis and Radiation Related Fracture Risk in Irradiated Patients.

Yaprak G, Gemici C, Seseogullari OO, Karabag IS, Cini N.

Front Oncol. 2020

4- Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy.

Yaprak G, Ozcelik M, Gemici C, Seseogullari O.

North Clin Istanbul. 2019

5- Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning.

Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H.

Radiat Oncol. 2018

6- Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer.

Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO.

BMC Cancer. 2018

7- Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience.

Ozyurt H, Ozden AS, Ozgen Z, Gemici C, Yaprak G.

Curr Oncol. 2017

8- Radiation field size and dose determine oncologic outcome in esophageal cancer.

Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A.

World J Surg Oncol. 2016

9- Is there any role of intravenous iron for the treatment of anemia in cancer?

Gemici C, Yetmen O, Yaprak G, Ozden S, Tepetam H, Ozyurt H, Mayadagli A.

BMC Cancer. 2016

10- Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.

Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M.

Tumour Biol. 2016

11- Whole-brain radiation therapy for brain metastases: detrimental or beneficial?

Gemici C, Yaprak G.

Radiat Oncol. 2015

12- SRS With or Without Whole-Brain Radiation Therapy for Those With 1 to 4 Brain Metastases: In Regard to Sahgal et al.

Gemici C, Yaprak G.

Int J Radiat Oncol Biol Phys. 2015

13- Neuroendocrine/squamous gastric collision tumor: A rare entity.

Erkol B, Tilki M, Comunoğlu N, Öven Ustaaloğlu BB, Aker F, Sürmelioglu A, Telli F, **Gemici C**, Kılıçoğlu ZG, Yeşil A.

Turk J Gastroenterol. 2014

14- Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants.

Ozden S, Ozgen Z, Ozyurt H, **Gemici C**, Yaprak G, Tepetam H, Mayadagli A.

World J Gastroenterol. 2015

15- Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer: in regard to Muijs et al.

Gemici C.

Int J Radiat Oncol Biol Phys. 2014

16- A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey.

Arıcan A, Bozkurt T, Bozcuk H, Demirkan B, Büyükberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, **Gemici C**, Ozdemir F, Ozdener F, Pekin B.

Support Care Cancer. 2014

17- Progression-free survival benefit or health-related quality-of-life advantage: which one to choose?

Gemici C.

J Clin Oncol. 2013

18- Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer.

Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, Kocak M.

Radiother Oncol. 2013

19- Co-existence of gastrointestinal stromal tumors with other primary neoplasms.

Sevinc A, Seker M, Bilici A, Ozdemir NY, Yildiz R, Ustaalioglu BO, Kalender ME, Dane F, Karaca H, **Gemici C**, Gumus M, Buyukberber S.

Hepatogastroenterology. 2011

20- Lhermitte's sign: Review with special emphasis in oncology practice.

Gemici C.

Crit Rev Oncol Hematol. 2010

21- Tumor lysis syndrome in solid tumors.

Gemici C.

J Clin Oncol. 2009

22- Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube.

Caglayan B, Torun E, Turan D, Fidan A, **Gemici C**, Sarac G, Salepci B, Kiral N.

Ann Surg Oncol. 2008

23- How can we determine the role of radiotherapy in the treatment of localized aggressive non-Hodgkin's lymphoma?

Gemici C, Salepci T.

J Clin Oncol. 2007

24- The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.

Gemici C.

Cancer. 2007

25- Tumour lysis syndrome in solid tumours.

Gemici C.

Clin Oncol (R Coll Radiol). 2006

26- Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy.

Dabak R, Uygur-Bayramicli O, **Gemici C**, Yavuzer D, Sargin M, Yildirim M.

World J Gastroenterol. 2006

27- Encapsulating peritonitis and familial Mediterranean fever.

Dabak R, Uygur-Bayramicli O, Aydin DK, Dolapçioğlu C, **Gemici C**, Erginel T, Turan C, Karadayi N.

World J Gastroenterol. 2005

28- Erythropoietin to treat anaemia in patients with head and neck cancer.

Gemici C.

Lancet. 2004

29- Is liver disease an octreotide side effect?

Uygur-Bayramicli O, **Gemici C.**

J Clin Gastroenterol. 2003

30- Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.

Belkacémi Y, Pène F, Touboul E, Rio B, Leblond V, Gorin NC, Laugier A, **Gemici C**, Housset M, Ozsahin M.

Strahlenther Onkol. 1998